CHINA NMPA ACCEPTS NEW DRUG APPLICATION FOR HS-10365 CAPSULES FOR THE TREATMENT OF RET FUSION-POSITIVE NSCLC
Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announces that the New Drug Application(NDA) of the Group’s innovative drug “HS-10365 capsules”, a potent and selective rearranged during transfection (RET) inhibitor, has been accepted by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
HS-10365 is a Class 1 innovative drug independently developed by the company. As a small-molecule, highly selective RET receptor tyrosine kinase inhibitor, it can act directly on intracellular protein tyrosine kinases, bind competitively with ATP, and inhibit tyrosine kinase phosphorylation, thereby effectively controlling tumor growth.
At the 114th Annual Meeting of the American Association for Cancer Research (AACR) in 2023, the preliminary result of the Phase I trial was first released[1]. The results showed that HS-10365 had an overall response rate (ORR) of 83.3% in treatment-naive patients with advanced RET fusion-positive NSCLC and 66.7% in previously treated NSCLC patients, demonstrating promising anti-tumor activity in patients with advanced RET fusion-positive NSCLC, along with manageable safety profile and good tolerability, while results from subsequent registration clinical trials will be disclosed at international conference recently.
Hansoh Pharma
Hansoh Pharma is a leading innovation-driven pharmaceutical company headquartered in China. The company is committed to addressing significant unmet medical needs in oncology, central nervous system (CNS) disorders, metabolic diseases, and autoimmune conditions. Hansoh Pharma has launched seven innovative drugs that generate product sales in the PRC, forming a rich product pipeline. great The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top three pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
Statements
1. This announcement is intended for healthcare professionals only and not for advertising purposes.
2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.
3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.
4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
The information contained in this release may include forward-looking statements related to Hansoh Pharma’s business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma’s control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions.
As such, investors should exercise caution when using this information to make investment decisions. Phrases such as “commit,” “expect,” “believe,” “predict,” “anticipate,” “forecast,” “intent,”“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.
